Figure Legends

Supplementary Figure 1. Patient flow in cost analysis using the JMDC Claims Database

The medical cost for TRD patients was calculated with the use of the JMDC Claims Database provided by JMDC Inc. Medical cost was calculated on the 4,211 TRD patients selected for this analysis using the inclusion/exclusion criteria from the 245,871 patients diagnosed as having depression between July 2016 and June 2019.


Supplementary Figure 2. Results of analysis at varying amounts reimbursed for each session of rTMS therapy

ICER was ¥1,428,627 (\$10,428)/QALY when the price for rTMS therapy used in the study by Nguyen et al. (150AUD: ¥14,286) was adopted into this model. ICER was ¥4,650,374 (\$33,944)/QALY when the prices for rTMS therapy used in the study by Voigt et al. (first session \$367: ¥50,279, second and subsequent sessions \$206: ¥28,222) were adopted. Reimbursement price for one session of rTMS therapy was identified to be ¥30,800 (\$225) at the ICER threshold of ¥5 million/QALY.

Supplementary Figure 1. Patient flow in cost analysis using the JMDC Claims Database

Patients for whom care records during the study period a		
	245,871	
	Patients not satifying the inclusion criteria ①	206,789
	- No definite diagnosis of depression during the study period	5,941
	- Three or more drugs used for the primary treatment	
	- No secondary treatment received within 30 days after the estimated last drug dose date during the primary treatment	206,789
Patients with the index date	39,082	
ſ	Patients not satisfying the inclusion criteria 2	11,227
	- No psychotropic prescription or admission to psychiatric ward during the follow-up period	10,208
!	- No psychotropic prescription during the follow-up period	10,336
	- No admission to the psychiatric ward during the follow-up period	36,844
	- Age less than 18 years at the time of index date	1,204
	27,855	22 644
· ·	Patients falling under any of the exclusion criteria	23,644
	 Definitely diagnosed as having severe depressive episode, mania, schizophrenia, epilepsy, convulsive attack, intracranial lesion, etc. accompanied by psychotic symptoms before the index date 	16,947
	- Definitely diagnosed as being pregnant during the follow-up period	
1	- Having received medical procedure with implant type medical device, etc. contraindicated for rTMS during the follow-up perio	403
!	- The study period does not cover the 180 days before the earliest definite diagnosis of depression	18,359
	- The baseline period cannot be secured	9,534
	- Follow-up period is less than 1 month	0
	- Records of admission available at the time of index date	275
Patients falling under none of the exclusion criteria	4,211	
Patients included in the analysis	4,211	

Supplementary Figure 2. Results of analysis at varying amounts reimbursed for each session of rTMS therapy



rTMS therapy price/session (yen(\$))

Supplementary Table 1. Summary of cost analysis using the JMDC Claims Database

Variable	Definition
Study period	July 2016 to June 2019
Index date	Secondary treatment starting date (date of antidepressant prescription within 30 days after the end of first treatment)
Follow-up period	From the index date for each patient to the last day with the record on the JMDC database
Duration of treatment	From the date of estimated last intake of antidepressant or the drug for augmentation therapy (date of prescription + number of days covered by prescription) to a point of time by which 31 days or more were without identifiable prescription of these drugs
Patients studied	3.
Inclusion	Diagnosed as having depression during the study period (Supplementary Table 2) and having begun to receive antidepressant treatment defined in Supplementary Table 3 after the diagnosis
	Having received secondary treatment within 30 days after the date of the last prescription for the primary treatment + the number of days covered by prescription (estimated date of last drug intake)
	Having received prescription of any of the psychotropics defined in
	Supplementary Table 3 or being admitted to a psychiatric ward during the follow-up period
Exclusion	Having been diagnosed as having severe depressive episode, mania, schizophrenia, epilepsy, convulsive attack, intracranial lesion, etc. accompanied by psychotic symptoms before the index date Having received medical procedure using a metallic or other device or any other material applied to the head or within 30 cm from the head during the follow-up period Having been diagnosed as being pregnant during the follow-up period
Data collected	The data on the following costs were collected during the treatment continued period
Drug costs at each treatment step	Calculated by averaging (weighted by the percentage of each drug prescribed) of the daily prescribed quantity of antidepressant or drug for augmentation therapy at each treatment line x drug price x monthly frequency of dosing
Inpatient care costs	Monthly costs of inpatient care after admission for a reason of depression
Outpatient care costs	Costs of outpatient care accompanied by prescription of antidepressant or drug for augmentation therapy
Outpatient test costs	Costs of tests conducted during outpatient visit accompanied by prescription of antidepressant or drug for augmentation therapy
ECT costs	Monthly costs of ECT applied to inpatients (192 cases) admitted after diagnosis of depression

Supplementary Table 2. Definition of depression

Variable	Definition	
	ICD10 code	ICD10 name
Moderate or severer depressive	F321	Moderate depressive episode
episode	F322	Severe depressive episode without psychotic symptoms
Moderate or severer recurrent depressive disorder	F331	Recurrent depressive disorder, current episode moderate
	F332	Recurrent depressive disorder, current severe episode without psychotic symptoms
Depressive episode, unspecified	F329	Depressive episode, unspecified
Recurrent depressive disorder, unspecified	F339	Recurrent depressive disorder, unspecified

Supplementary Table 3. Definition of antidepressants/psychotropics

Classification	Active Ingredient	
Antidepressants		
Tricyclic antidepressants	Amitriptyline hydrochloride	
	Amoxapine	
	Imipramine hydrochloride	
	Clomipramine hydrochloride	
	Dosulepin hydrochloride	
	Trimipramine maleate	
	Nortriptyline hydrochloride	
	Lofepramine hydrochloride	
Tetracyclic antidepressants	Setiptiline maleate	
	Maprotiline hydrochloride	
	Mianserin hydrochloride	
SSRI	Escitalopram oxalate	
	Sertraline hydrochloride	
	Paroxetine hydrochloride	
	Fluvoxamine maleate	
SNRI	Duloxetine hydrochloride	
	Milnacipran hydrochloride	
	Venlafaxine hydrochloride	
SARI	Trazodone hydrochloride	
Serotonin reuptake inhibitors/serotonin receptor modulators	Vortioxetine hydrobromide	
NaSSA	Mirtazapine	
Psychotropics		
Tricyclic antidepressants	Amitriptyline hydrochloride	
	Amoxapine	
	Imipramine hydrochloride	
	Clomipramine hydrochloride	
	Dosulepin hydrochloride	
	Trimipramine maleate	
	Nortriptyline hydrochloride	
-	Lofepramine hydrochloride	
Tetracyclic antidepressants	Setiptiline maleate	
	Maprotiline hydrochloride	
	Mianserin hydrochloride	
SARI	Trazodone hydrochloride	
Lithium	Lithium carbonate	
T3/T4 preparations	Levothyroxine sodium	
	Dry thyroid	
	Liothyronine sodium	
Aripiprazole	Aripiprazole	
Quetiapine	Quetiapine fumarate	
Olanzapine	Olanzapine	
Risperidone	Risperidone	

Supplementary Table 4. List of parameters used for scenario analysis

							
Parameter	Scenario analysis value	Source					
TMS therapy continued as Step 2 maintenance phase treatment							
Relapse rate in Step 2 maintenance	9.1%/year	(Haesebaert et al., 2018)					
phase treatment with rTMS therapy	•	,					
Recurrence rate in Step 2	24.20/ haar	() () () () () () () () () () () () () (
maintenance phase treatment with	24.2%/year	(Wang et al., 2017)					
rTMS therapy Cost of Step 2 maintenance phase		JMDC Claims Database,					
	¥69,379 (\$506)/month						
treatment with rTMS therapy Expert opinion 2) rTMS therapy applied as Step 3 acute phase treatment upon recurrence following Step 2 rTMS							
therapy	mase treatment upon recurrenc	e following Step 2 i fivis					
Response rate in Step 3 acute phase		,					
treatment with rTMS therapy	84.2%/month	(Janicak et al., 2010)					
Remission rate in Step 3 acute phase	05.00//						
treatment with rTMS therapy	35.8%/month	(Sackeim et al., 2020)					
Relapse rate after to Step 3 acute	04.00/ /	(14)					
phase treatment with rTMS therapy	24.2%/year	(Wang et al., 2017)					
Recurrence rate after Step 3 acute	24.2%/year	() () () () () () () () () () () () () (
phase treatment with rTMS therapy	24.2%/year	(Wang et al., 2017)					
Cost of Step 3 acute phase treatment	¥370,892 (\$2,707)/month	JMDC Claims Database,					
with rTMS therapy	,	Expert opinion					
rTMS therapy plus antidepressant treat	ment applied as Step 2 acute pl	hase treatment					
Response rate in Step 2 acute phase		`					
treatment with rTMS plus	68.9%/month	(Sackeim et al., 2020)					
antidepressant treatment							
Remission rate in Step 2 acute phase		`					
treatment with rTMS plus	35.8%/month	(Sackeim et al., 2020)					
antidepressant treatment							
Relapse rate after Step 2 acute phase	45.00/ ///	(14)					
treatment with rTMS plus	15.9%/year	(Wang et al., 2017)					
antidepressant treatment Recurrence rate after Step 2 acute							
phase treatment with rTMS plus	15.9%/year	(Mana et al. 2017)					
antidepressant treatment	13.970/year	(Wang et al., 2017)					
Cost of Step 2 acute phase treatment							
with rTMS plus antidepressant	¥384,975 (\$2,810)/month	JMDC Claims Database,					
treatment	(ψ2,010)/ποπατ	Expert opinion					
Productivity loss due to depression take	en into consideration						
Employment rate among patients with		(Statistics Bureau of					
depression	60.40%	Japan, 2021)					
During outpatient treatment		омран, 202 г/					
Absenteeism	14.10%	(Yamabe et al., 2019)					
Presenteeism	42.70%	(Yamabe et al., 2019)					
During inpatient treatment	42.7070	(Talliabe et al., 2019)					
Absenteeism	100%	Assumption					
Presenteeism	100%	Assumption					
Mean wage (annual)	10070	Assumption					
40-44 years	¥5,323,700 (\$38,859)						
45-49 years	¥5,552,900 (\$40,532)						
50-54 years	¥5,887,100 (\$42,972)	(Ministry of Health, Labour					
55-59 years	¥5,807,500 (\$42,391)	and Welfare of Japan,					
60-64 years	¥4,356,100 (\$31,796)	2021b)					
65-69 years	¥3,615,700 (\$26,392)	- /					
70 years or older	¥3,264,100 (\$23,826)						
•							